Pre-Clinical News | Medical XPRT

Creative Enzymes Launches DSPE-PEG-Maleimide for Targeted Drug Delivery

Creative Enzymes, a professional enzyme provider located in New York, always hammers at researches and trials in order to provide customers with various enzymes as many as possible. The product manager of Creative Enzymes announced the launch of DSPE-PEG(5000) Maleimide and DSPE-PEG(2000) Maleimide, which can be used to synthesize functional conjugates. DSPE-PEG-Maleimide (DSPE-PEG-MAL) is a ...

Jun. 22, 2021

By Creative Enzymes

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant Program Call for Submissions to Support Research in Immuno-oncology

Thermo Fisher Scientific today announced that submissions are now open for the Oncomine Clinical Research Grant program to support clinical research projects in oncology. This grant aims to provide funding for high-quality molecular profiling studies focusing on the impact of immune-based treatments for cancer patients. Through the Oncomine Clinical Research Grant program, Thermo Fisher will ...

Jun. 16, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Thermo Fisher Scientific Introduces New Quick to Clinic Solution to Help Biologic Drug Developers Accelerate Preclinical Development at BIO Digital 2021

BIO DIGITAL 2021 – New and emerging biopharma companies working on early development can now leverage a better lab to clinic drug development solution designed to accelerate the journey from DNA to drug product. The enhanced Quick to Clinic solution from Thermo Fisher Scientific may help biopharma companies reach Phase I/First-In-Human trials and file for Investigational New Drug (IND) ...

Jun. 14, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Creative Biolabs Upgrades Oncolytic Virus Product List for Immunotherapy Research

As early as around 1800, doctors discovered that certain cancer patients would have their symptoms reduced after being briefly infected with viruses. With the advancement of genetic engineering technology, the idea that viruses have the potential to improve and mediate immunotherapy has been established. Oncolytic viruses (OVs) are such kind of viruses that can replicate in tumor tissues, and ...

May 27, 2021

By Creative Biolabs

Creative Enzymes Upgrades Multiple Diagnostic Enzyme Products for Clinical and Diagnostic Research

Creative Enzymes, the world’s leading diagnostic enzyme production company, has been committed to providing customers with various enzyme products and services for medical and research diagnosis. Relying on its professional team and the most advanced technology, as well as high-quality products and services, it has gained solid reputation. Recently, Creative Enzymes has announced multiple ...

May 25, 2021

By Creative Enzymes

Thermo Fisher Scientific and University of California, San Francisco to Open Cell Therapy cGMP Manufacturing and Collaboration Center

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, and the University of California, San Francisco (UCSF) today announced they have formed a strategic alliance to accelerate the development and manufacturing of cell-based therapies. Under the agreement, Thermo Fisher will build and operate a 44,000-square-foot, state-of-the-art cell therapy development, manufacturing ...

May 20, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

China International Pharmaceutical Machinery Expo (CIPM)

Puretech Process Systems Ltd’s distributor ITS Science & Medical will be representing us at the China International Pharmaceutical Machinery Exposition (CIPM) 10 -12th May 2021. James Steptoe, our Global Sales Manager, will be supporting ITS remotely on Zoom. To contact James please send him a ...

May 6, 2021

By Puretech Process Systems Limited

Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its participation in a newly expanded investigator-initiated Phase 2 clinical trial called Comparing COVID-19 Vaccine Schedule Combinations – Stage 2 (Com-COV2), to be conducted by the University of Oxford and supported by the UK Vaccines Taskforce. ...

May 3, 2021

By Novavax

Exosome Services at Creative Biolabs to Accelerate Lung Cancer Research

As the incidence and mortality of lung cancer rank among the highest all over the world, lung cancer diagnostics and treatment are the most researched paper topics. Research has reported that exosomes derived from lung cancer are the most promising biomarkers for early diagnosis, prognosis, and treatment of lung cancer. With years of experience in this field, Creative Biolabs provides exosome ...

Apr. 28, 2021

By Creative Biolabs

Thermo Fisher Scientific Recognizes Significance of FDA Approval of First CAR T Cell Immunotherapy for Multiple Myeloma with Donation to Leukemia and Lymphoma Society

Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of ...

Apr. 28, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

Scivita Medical Raises Nearly RMB0.4 Billion in Series a Funding Round and Strives to Build a World-leading Platform for Innovative Products in Endoscope and Related Fields

Scivita Medical Technology Co., Ltd. ('Scivita Medical*) today announced that it has raised nearly RMB0.4 Billion in Series A funding round, which has become one of the highest financing projects in the field of endoscope in China in recent years. The investment was jointly led by GL Ventures and Lilly Asia Ventures with contribution from Matrix Partners China, Medtronic, Chengwei Capital and ...

Apr. 26, 2021

By Scivita Medical Technology Co., Ltd.

Malaria Vaccine Phase 2b Clinical Trial Results Published in Preprints with The Lancet

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the pre-print publication of data from a Phase 2b clinical trial in children demonstrating 77 percent efficacy for a malaria vaccine candidate, R21, created by the University of Oxford that includes Novavax' Matrix-M™ adjuvant and is licensed to Serum ...

Apr. 23, 2021

By Novavax

Neutralizing Antibody Development for SARS-CoV-2 Available at Creative Biolabs

The continuous spread of COVID-19 has become a threat to global health and even has led to a global economic crisis. Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, ...

Apr. 16, 2021

By Creative Biolabs

Thermo Fisher Scientific to Acquire PPD, Inc., a Leading Clinical Research Organization

Establishes Thermo Fisher as a global leader in the attractive and high growth clinical research services industry Adds highly complementary services for the company's fastest growing end market Offers both meaningful cost and revenue synergies which will further accelerate growth Expected to be immediately and significantly accretive to Adjusted Earnings Per Share (EPS)¹ after close ...

Apr. 15, 2021

By Thermo Fisher Scientific, LIMS & Laboratory Software

AACR Presentation #1731 : EXS21546, a non-CNS penetrant A2AR-selective antagonist for anti-cancer immunotherapy

Our AACR Presentation #1731 is now available. Follow this link to the AACR web site and this link to see our Poster: Abstract Elevated levels of adenosine found in the tumor microenvironment have been highlighted as a potential mechanism contributing to the restricted efficacy of immune checkpoint inhibitors. While the advent of these inhibitors has brought significant benefit to patients with ...

Apr. 12, 2021

By Exscientia

Exscientia Announces First AI-Designed Immuno-Oncology Drug to Enter Clinical Trials

Company’s technologies and drug-hunting expertise now responsible for world’s first and second AI-designed drugs to enter Phase I testing Exscientia, a leading artificial intelligence (AI) driven pharmatech company, today announced the first AI-designed molecule for immuno-oncology to enter human clinical trials. The A2a receptor antagonist, which is in development for adult patients ...

Apr. 9, 2021

By Exscientia

Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%

The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. ‍ Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...

Apr. 8, 2021

By Benevolent

Proud to be supporting the COVID-19 vaccine supply chain in the United Kingdom

Puretech’s AquaZero distillation system was recently supplied to Scotland based contract manufacturing organisation Andersen Caledonia. The system will enable the company to wash glass vials prior to sterile packing in its ISO 5 cleanroom. The vials will then be supplied to be filled with vaccines. The AquaZero Still generates Water for Injection (WFI) and Pure Steam (PS) at ...

Apr. 7, 2021

By Puretech Process Systems Limited

Radiology partners selects Aidoc to Accelerate the use of AI as the standard of Care in Radiology

Radiology Partners (RP), the leading radiology practice in the U.S., announced today that it has selected Aidoc, the leading provider of artificial intelligence (AI) solutions for medical imaging, to offer unparalleled AI capabilities to its hospitals and health systems, and to accelerate the adoption of AI as the standard of care in radiology. “AI has the potential to unlock enormous ...

Apr. 6, 2021

By Aidoc

Evaxion Biotech Announces Q4 and Full-Year 2020 Financial Results and Provides Business Update

Successfully completed initial public offering on U.S. Nasdaq in February 2021, raising gross proceeds of $30 million Clinical development on track with dosing of first patient in Phase 1/2a melanoma trial of cancer vaccine EVX-02 Cash reserves of $5.8 million at December 31, 2020 plus funds from IPO provide funding for at least 12 months from the date of completion of the IPO COPENHAGEN, ...

Apr. 6, 2021

By Evaxion Biotech A/S